Thrombocytosis associated with enoxaparin: A very rare cause in newborns.
Newborn infants are most vulnerable to the development of thrombosis because of the developing neonatal hemostatic system, perinatal risk factors and different types of medical conditions. Enoxaparin is the current anticoagulant of choice with advantages for the treatment of neonatal thrombosis. Thrombocytosis induced by enoxaparin has been reported as a rare adverse effect of this medication in adults. However, to our knowledge, in newborns there have been no reported cases to date of thrombocytosis induced by enoxaparin.
Tonbul
Alparslan
A
Fatih University School of Medicine, Department of Pediatrics, Division of Neonatology, Ankara, Turkey.
Uras
Nurdan
N
Tayman
Cuneyt
C
Halici
Tugba
T
Polat
Aziz
A
Mansur Tatli
Mustafa
M
D000293:Adolescent; D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D017984:Enoxaparin / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D011247:Pregnancy; D013922:Thrombocytosis / Q000139:chemically induced*; D013927:Thrombosis / Q000188:drug therapy
D000925:Anticoagulants; D017984:Enoxaparin